Sign in

Matthew Gilmor

Director and Senior Equity Research Analyst at Keybanc

Matthew Gillmor is a Director and Senior Equity Research Analyst at KeyBanc Capital Markets, specializing in healthcare services with coverage of major companies such as UnitedHealth Group, HCA Healthcare, Tenet Healthcare Corporation, Acadia Healthcare, and Privia Health Group. His analyst performance since joining KeyBanc in 2024 includes a 25% profitable recommendation rate and an average return of -13.5%, with a recent top rating on Privia Health Group delivering a 13.7% positive return. Gillmor began his career in equity research at Robert W. Baird & Co., where he spent 13 years covering healthcare services and technology, and also served as head of investor relations at Agilon Health before joining KeyBanc. He holds a CFA charter and is FINRA registered with Series 7, 63, 86, and 87 licenses.

Matthew Gilmor's questions to BrightSpring Health Services (BTSG) leadership

Question · Q3 2025

Matthew Gilmor asked for clarification on the components of the EBITDA guidance raise, specifically if it reflects a combination of core performance and pulling through efficiency efforts. He also inquired about any changes in thinking regarding value-based care accruals and the potential for shared savings later in the year.

Answer

CFO Jen Phipps confirmed that the EBITDA guidance raise reflects both core performance and the realization of efficiency efforts. CEO Jon Rousseau stated that clarity has been gained, and some shared savings are now expected to be realized from value-based care contracts, following recent news about last year's performance.

Ask follow-up questions

Question · Q3 2025

Matthew Gilmor sought clarification on the components of BrightSpring's EBITDA guidance raise, specifically if it reflected a combination of core performance and accelerated efficiency efforts. He also inquired about any changes in thinking regarding value-based care accruals and the potential for realizing shared savings later in the year.

Answer

CFO Jen Phipps confirmed that the EBITDA guidance raise was indeed a combination of core performance and pulling through efficiency efforts. CEO Jon Rousseau stated that the company has gained clarity and expects to realize some shared savings from value-based care accruals, indicating a potential opportunity.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts